COVID-19 backing consolidation in spine industry
The main trend in the spine industry, the specialist explained, is the development of enabling technologies, such as robotics and computer-assisted solutions. “Now interestingly, NuVasive was really at the forefront of that, I’d say, four, five years ago”, but it remains to be seen whether the company will make up lost ground with the release of Pulse, a newer technology.
COVID-19 could accelerate consolidation: “I believe COVID is only going to, I wouldn’t say in every single account, but, across the board, it’s going to continue to consolidate the amount of vendors in the hospital.” Healthcare providers will want to reduce the amount of company representatives visiting hospitals owing to safety concerns.
The specialist also provided their thoughts on X360, which pieces together several of NuVasive’s products into one system. “Long story short, everybody is coming out with their version of X360. NuVasive obviously has experience and more data on their side than most other companies do.”
Meanwhile, Pulse had the release for its spinal robot pushed back. “Pulse is going to give you all of the tools necessary from a computer-assisted technology platform, from being very objective in the OR [operating room] and being able to verify the correction that you’re getting and being able to do your neuromonitoring and… specific steps within the actual surgery”, the specialist commented.
The Interview also covered R&D spending, global markets and a 12-18 month outlook for the company.
To access all the human insights from Third Bridge Forum’s NuVasive Medical Devices – Competitive Analysis & Q4 2020 Outlook Interview, click here to view the full transcript.
The information used in compiling this document has been obtained by Third Bridge from experts participating in Forum Interviews. Third Bridge does not warrant the accuracy of the information and has not independently verified it. It should not be regarded as a trade recommendation or form the basis of any investment decision.
For any enquiries, please contact firstname.lastname@example.org